- Home
- SIGA vs AUTL Comparison
SIGA vs AUTL Comparison
Compare SIGA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- AUTL
- Stock Information
- Founded
- SIGA 1995
- AUTL 2014
- Country
- SIGA United States
- AUTL United Kingdom
- Employees
- SIGA N/A
- AUTL N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SIGA Health Care
- AUTL Health Care
- Exchange
- SIGA Nasdaq
- AUTL Nasdaq
- Market Cap
- SIGA 422.9M
- AUTL 359.3M
- IPO Year
- SIGA 1997
- AUTL 2018
- Fundamental
- Price
- SIGA $6.03
- AUTL $2.36
- Analyst Decision
- SIGA
- AUTL Strong Buy
- Analyst Count
- SIGA 0
- AUTL 5
- Target Price
- SIGA N/A
- AUTL $9.32
- AVG Volume (30 Days)
- SIGA 458.7K
- AUTL 2.5M
- Earning Date
- SIGA 07-31-2025
- AUTL 05-08-2025
- Dividend Yield
- SIGA 9.95%
- AUTL N/A
- EPS Growth
- SIGA N/A
- AUTL N/A
- EPS
- SIGA 0.67
- AUTL N/A
- Revenue
- SIGA $120,330,310.00
- AUTL $9,011,000.00
- Revenue This Year
- SIGA N/A
- AUTL $371.59
- Revenue Next Year
- SIGA $95.31
- AUTL $165.71
- P/E Ratio
- SIGA $8.99
- AUTL N/A
- Revenue Growth
- SIGA N/A
- AUTL N/A
- 52 Week Low
- SIGA $4.95
- AUTL $1.11
- 52 Week High
- SIGA $12.83
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- SIGA 51.95
- AUTL 81.27
- Support Level
- SIGA $5.86
- AUTL $2.04
- Resistance Level
- SIGA $6.23
- AUTL $1.79
- Average True Range (ATR)
- SIGA 0.23
- AUTL 0.13
- MACD
- SIGA -0.00
- AUTL 0.09
- Stochastic Oscillator
- SIGA 57.14
- AUTL 94.66
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.